Cardiotoxic effects of antitumor chemotherapy in the treatment of a patient with gastric adenocarcinoma
https://doi.org/10.33667/2078-5631-2026-4-50-55
Abstract
Background. Fluoropyrimidines such as 5-fluorouracil and its oral prodrug capecitabine are widely used in treating gastrointestinal malignancies but are associated with potentially severe cardiotoxicity. Nephrotoxicity associated with platinum-based therapies (Cisplatin, Oxaliplatin).
Case summary. We present the case of a 60-year-old man with resected gastric adenocarcinoma (T3N 2M0) treated with adjuvant FOLFOX (5-fluorouracil plus oxaliplatin). On the first day of the second cycle, he developed tachycardia. Electrocardiogram showed supraventricular tachycardia and on next day-atrial flutter, while echocardiography demonstrated reduced ejection fraction. Troponin I was 2.7. Chemotherapy was discontinued, and a reduced dose of capecitabine was recommended.
Conclusions. This case illustrates the cardiotoxicity of oxaliplatin, with both supraventricular tachycardia and atrial flutter, while echocardiography demonstrated reduced ejection fraction.
About the Authors
N. D. Karseladze
NAKFF Medical Clinic LLC
Russian Federation
Russian Federation
Karseladze Natalia D., PhD Med Sci, cardiologist, ultrasound diagnostics specialist
Moscow
P. S. Sergeev
NAKFF Medical Clinic LLC
Russian Federation
Russian Federation
Sergeev Peter S., PhD Med Sci, chief physician, highest category physician, surgical oncologist, oncologist, chemotherapist
Moscow
A. O. Mezhueva
NAKFF Medical Clinic LLC
Russian Federation
Russian Federation
Mezhueva Agnia O., head of Dept of Antitumor Drug Therapy, oncologist, chemotherapist
Moscow
V. A. Pirozhnikov
NAKFF Medical Clinic LLC
Russian Federation
Russian Federation
Pirozhnikov Vladimir A., head of Clinical and Diagnostic Dept, cardiologist, general practitioner
Moscow
References
1. Clinical Guidelines «Stomach Cancer. 2022. (In Russ.).
2. Alyabyeva A.A., Mal G.S. Cardiotoxic effects caused by the use of antimetabolites in chemotherapy of oncological diseases. CardioSomatics. 2021; 12 (3): 177–182. (In Russ.). DOI: 10.26442/22217185.2021.3.20109
3. Matyash M.G., Kravchuk T.L., Vysotskaya V.V. et al. Non-anthracycline cardiotoxicity. Siberian Journal of Oncology. 2009; 5 (35): 71–82. (In Russ.).
4. Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer: A Nationwide Registry-Based Study. JACC: Cardiooncology. 2021 Dec; 3 (5): 725–733.
5. Stadnichenko A.V., Krasnopolsky Yu.M., Shvets V.I. Some Aspects of Obtaining the Liposomal Form of Oxaliplatin. Fine Chemical Technologies. 2015; 10 (1): 60–65. (In Russ.).
6. Breder V.V. Oxaliplatin in Systemic Chemotherapy of Advanced Colorectal Cancer. Russian Journal of Medical Oncology. 2006; 14: 1047. (In Russ.).
7. Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data. Guowen Feng, Xiaodan Zhou, Jia Chen. Original Research 11/ Jan/2023. (In Russ.). DOI: 10.3389/fonc.2022.1012093
Review
For citations:
Karseladze N.D., Sergeev P.S., Mezhueva A.O., Pirozhnikov V.A. Cardiotoxic effects of antitumor chemotherapy in the treatment of a patient with gastric adenocarcinoma. Medical alphabet. 2026;(4):50-55. (In Russ.) https://doi.org/10.33667/2078-5631-2026-4-50-55
Views:
153
JATS XML
Email this article 